A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia

Gynecologic Oncology

Volumn 134, Issue 2, 2014, Pages 274-280

  Castonguay, Vincent ^a   Lheureux, Stephanie ^a   Welch, Stephen ^b   MacKay, Helen J ^a   Hirte, Hal ^c   Fleming, Gini ^d   Morgan, R ^e   Wang, Lisa ^a   Blattler, Chantale ^a   Ivy, Percy S ^f   Oza, Amit M ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c JURAVINSKI CANCER CENTRE   (Canada)

^d UNIVERSITY OF CHICAGO   (United States)

^e City of Hope   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Endometrial cancer; Phase II; Recurrence; Sunitinib

Indexed keywords

SUNITINIB;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; METASTASIS; METASTATIC ENDOMETRIUM CARCINOMA; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; TREATMENT DURATION; VERY ELDERLY;

ENDOMETRIAL CANCER; PHASE II; RECURRENCE; SUNITINIB;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CALIFORNIA; CARCINOSARCOMA; CHICAGO; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONTARIO; PYRROLES;

EID: 84905568519     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.05.016     Document Type: Article

References (41)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 1 2013 11 30
2. D.S. Dizon Treatment options for advanced endometrial carcinoma Gynecol Oncol 117 2 2010 373 381
3. D. Tsoref, and A.M. Oza Recent advances in systemic therapy for advanced endometrial cancer Curr Opin Oncol 23 5 2011 494 500
4. D. Miller, V. Filiaci, G. Fleming, R. Mannel, D. Cohn, and T. Matsumoto et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carinoma: a Gynecologic Oncology Group study Gynecol Oncol 125 2012 [abstr. 771]
5. J.D. Wright, N.I. Barrena Medel, J. Sehouli, K. Fujiwara, and T.J. Herzog Contemporary management of endometrial cancer Lancet 379 9823 2012 1352 1360
6. K.M. Sjoquist, J. Martyn, R.J. Edmondson, and M.L. Friedlander The role of hormonal therapy in gynecological cancers - current status and future directions Int J Gynecol Cancer 21 7 Oct 2011 1328 1333
7. D.S. Dizon, J.A. Blessing, D.S. McMeekin, S.K. Sharma, P. Disilvestro, and R.D. Alvarez Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P J Clin Oncol 27 19 2009 3104 3108
8. S. Lincoln, J.A. Blessing, R.B. Lee, and T.F. Rocereto Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 88 3 2003 277 281
9. D.S. Miller, J.A. Blessing, S.S. Lentz, and S.E. Waggoner A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 87 3 2002 247 251
10. F.M. Muggia, J.A. Blessing, J. Sorosky, and G.C. Reid Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 20 9 2002 2360 2364
11. T. Hogberg What is the role of chemotherapy in endometrial cancer? Curr Oncol Rep 13 6 Dec 2011 433 441
12. E. Sivridis Angiogenesis and endometrial cancer Anticancer Res 21 6B 2001 4383 4388
13. D.S. McMeekin, M.W. Sill, D. Benbrook, K.M. Darcy, D.J. Stearns-Kurosawa, and L. Eaton et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study Gynecol Oncol 105 2 2007 508 516
14. A. Giatromanolaki, E. Sivridis, R. Brekken, P.E. Thorpe, P. Anastasiadis, and K.C. Gatter et al. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications Cancer 92 10 Nov 15 2001 2569 2577
15. N. Seki, J. Kodama, A. Hongo, Y. Miyagi, M. Yoshinouchi, and T. Kudo Vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer Eur J Cancer 36 1 2000 68 73
16. A. Talvensaari-Mattila, Y. Soini, and M. Santala VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma Tumour Biol 26 2 2005 81 87
17. Y. Okoyama, S. Sato, M. Futagami, Y. Fukushi, T. Sakamoto, and M. Umemoto et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma Gynecol Oncol 77 3 2000 413 418
18. T. Kaku, T. Kamura, N. Kinukawa, H. Kobayashi, K. Sakai, and N. Tsuruchi et al. Angiogenesis in endometrial carcinoma Cancer 80 4 1997 741 747
19. H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, and W. Heim et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
20. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
21. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 Dec 29 2011 2473 2483
22. R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, and S. Oudard et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 22 2009 3584 3590
23. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2006 2542 2550
24. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, and P.G. Rose et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 29 16 2011 2259 2265
25. L.Q.M. Chow, and S.G. Eckhardt Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 7 2007 884 896
26. E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath, and C. Lombard-Bohas et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 6 2011 501 513
27. G.D. Demetri, A.T. van Oosterom, C.R. Garrett, M.E. Blackstein, M.H. Shah, and J. Verweij et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 2006 1329 1338
28. C.H. Barrios, D. Hernandez-Barajas, M.P. Brown, S.-H. Lee, L. Fein, and J.-H. Liu et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma Cancer 118 5 2012 1252 1259
29. G.P. Sutton, J.A. Blessing, L.R. DeMars, D. Moore, T.W. Burke, and E.C. Grendys A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium Gynecol Oncol 63 1 1996 25 27
30. A.M. Oza, L. Elit, M.-S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 24 2011 3278 3285
31. H. Mackay, S. Welch, M. Tsao, J. Biago, L. Elit, and P. Ghatage et al. Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192 2011 ASCO
32. N. Colombo, D.S. McMeekin, P.E. Schwartz, C. Sessa, P.A. Gehrig, and R. Holloway et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial Br J Cancer 108 5 2013 1021 1026
33. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 23 2010 5415 5419
34. I. Ray-Coquard, L. Favier, B. Weber, C. Roemer-Becuwe, P. Bougnoux, and M. Fabbro et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO Br J Cancer 108 9 2013 1771 1777
35. H.S. Nimeiri, A.M. Oza, R.J. Morgan, D. Huo, L. Elit, and J.A. Knost et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 117 1 2010 37 40
36. B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, and M.E. Gore et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 9 2011 763 773
37. B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, and R.J. Motzer Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother Pharmacol 66 2 2010 357 371
38. B.A. Feinberg, P. Jolly, S.-T. Wang, B. Fortner, J. Scott, and J. Gilmore et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics Med Oncol 29 2 2012 786 794
39. K. Lindemann, L.J. Vatten, M. Ellstrøm-Engh, and A. Eskild Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study Br J Cancer 98 9 2008 1582 1585
40. R.L. Coleman, M.W. Sill, H.A. Lankes, A.N. Fader, N.J. Finkler, and J.S. Hoffman et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study Gynecol Oncol 127 3 2012 538 543
41. P.S. Lee, and A.A. Secord Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway Cancer Treat Rev 40 4 2014 507 512